GNOM.L vs. GXLV.L

Last updated Jul 18, 2026

GNOM.L (Global X Genomics & Biotechnology UCITS ETF USD (Acc)) and GXLV.L (SPDR S&P US Health Care Select Sector UCITS ETF) are both exchange-traded funds - GNOM.L is a Genomics fund tracking the Solactive Genomics v2 Index, while GXLV.L is a Health & Biotech Equities fund tracking the MSCI World/Health Care NR USD. Both are passively managed. Over the past 3 years, GNOM.L returned 3.68%/yr vs 8.44%/yr for GXLV.L. At a 0.42 correlation, their price movements are largely independent. GNOM.L charges 0.50%/yr vs 0.15%/yr for GXLV.L.

Performance

GNOM.L vs. GXLV.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Global X Genomics & Biotechnology UCITS ETF USD (Acc) (GNOM.L) and SPDR S&P US Health Care Select Sector UCITS ETF (GXLV.L). The values are adjusted to include any dividend payments, if applicable.

Different Trading Currencies

GNOM.L is traded in USD, while GXLV.L is traded in GBP. To make them comparable, the GXLV.L values have been converted to USD using the latest available exchange rates.

Returns By Period

In the year-to-date period, GNOM.L achieves a 19.36% return, which is significantly higher than GXLV.L's 4.65% return.

GNOM.L

• 1D: -1.72%
• 1M: 5.07%
• 6M: 13.12%
• YTD: 19.36%
• 1Y: 57.61%
• 3Y*: 3.68%
• 5Y*: —
• 10Y*: —

GXLV.L

• 1D: 0.00%
• 1M: 7.41%
• 6M: 4.12%
• YTD: 4.65%
• 1Y: 23.02%
• 3Y*: 8.44%
• 5Y*: -0.47%
• 10Y*: 6.72%

*Multi-year figures are annualized to reflect compound growth (CAGR)

GNOM.L vs. GXLV.L - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
GNOM.L Global X Genomics & Biotechnology UCITS ETF USD (Acc)	19.36%	19.30%	-17.99%	-5.77%	-37.21%	-8.59%
GXLV.L SPDR S&P US Health Care Select Sector UCITS ETF	4.65%	15.16%	2.00%	1.16%	-27.54%	4.84%

Correlation

The correlation between GNOM.L and GXLV.L is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.43
Correlation (3Y) Calculated over the trailing 3-year period	0.42
Correlation (All Time) Calculated using the full available price history since Nov 2, 2021	0.42

Return for Risk

GNOM.L vs. GXLV.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GNOM.L

GNOM.L Risk / Return Rank: 75
GNOM.L Sharpe Ratio Rank: 79
GNOM.L Sortino Ratio Rank: 81
GNOM.L Omega Ratio Rank: 71
GNOM.L Calmar Ratio Rank: 79
GNOM.L Martin Ratio Rank: 63

GXLV.L

GXLV.L Risk / Return Rank: 51
GXLV.L Sharpe Ratio Rank: 56
GXLV.L Sortino Ratio Rank: 62
GXLV.L Omega Ratio Rank: 51
GXLV.L Calmar Ratio Rank: 49
GXLV.L Martin Ratio Rank: 39

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GNOM.L vs. GXLV.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology UCITS ETF USD (Acc) (GNOM.L) and SPDR S&P US Health Care Select Sector UCITS ETF (GXLV.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	GNOM.L	GXLV.L	Difference
Sharpe ratio: Return per unit of total volatility	1.92	1.52	+0.40
Sortino ratio: Return per unit of downside risk	2.75	2.35	+0.40
Omega ratio: Gain probability vs. loss probability	1.31	1.26	+0.05
Calmar ratio: Return relative to maximum drawdown	3.03	2.21	+0.82
Martin ratio: Return relative to average drawdown	8.28	5.43	+2.85

GNOM.L vs. GXLV.L - Sharpe Ratio Comparison

The current GNOM.L Sharpe Ratio is 1.92, which is comparable to the GXLV.L Sharpe Ratio of 1.52. The chart below compares the historical Sharpe Ratios of GNOM.L and GXLV.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

GNOM.L vs. GXLV.L - Drawdown Comparison

The maximum GNOM.L drawdown since its inception was -69.32%, which is greater than GXLV.L's maximum drawdown of -37.17%. Use the drawdown chart below to compare losses from any high point for GNOM.L and GXLV.L.

Drawdown Indicators

	GNOM.L	GXLV.L	Difference
Max Drawdown Largest peak-to-trough decline	-69.32%	-37.17%	-32.15%
Max Drawdown (1Y) Largest decline over 1 year	-18.91%	-10.45%	-8.46%
Max Drawdown (3Y) Largest decline over 3 years	-44.77%	-17.58%	-27.19%
Max Drawdown (5Y) Largest decline over 5 years	—	-37.17%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-37.17%	—
Current Drawdown Current decline from peak	-38.51%	-10.04%	-28.47%
Average Drawdown Average peak-to-trough decline	-47.15%	-15.56%	-31.59%
Ulcer Index Depth and duration of drawdowns from previous peaks	6.94%	4.25%	+2.69%

Volatility

GNOM.L vs. GXLV.L - Volatility Comparison

Global X Genomics & Biotechnology UCITS ETF USD (Acc) (GNOM.L) has a higher volatility of 8.62% compared to SPDR S&P US Health Care Select Sector UCITS ETF (GXLV.L) at 5.37%. This indicates that GNOM.L's price experiences larger fluctuations and is considered to be riskier than GXLV.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	GNOM.L	GXLV.L	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.62%	5.37%	+3.25%
Volatility (6M) Calculated over the trailing 6-month period	22.27%	11.46%	+10.81%
Volatility (1Y) Calculated over the trailing 1-year period	29.93%	15.26%	+14.67%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.10%	18.35%	+14.75%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.10%	19.85%	+13.25%

GNOM.L vs. GXLV.L - Expense Ratio Comparison

GNOM.L has a 0.50% expense ratio, which is higher than GXLV.L's 0.15% expense ratio.

Dividends

GNOM.L vs. GXLV.L - Dividend Comparison

Neither GNOM.L nor GXLV.L has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both GNOM.L and GXLV.L in my portfolio?

GNOM.L and GXLV.L have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, GNOM.L or GXLV.L?

On fees, GXLV.L is cheaper at 0.15% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, GNOM.L or GXLV.L?

GXLV.L is cheaper with a 0.15% expense ratio, compared with 0.50% for GNOM.L.

What is the main difference between GNOM.L and GXLV.L?

GNOM.L is categorized as Genomics, while GXLV.L is Health & Biotech Equities. GNOM.L tracks Solactive Genomics v2 Index, while GXLV.L tracks MSCI World/Health Care NR USD. They also come from different issuers: Global X and State Street. Their fees differ too: 0.50% for GNOM.L and 0.15% for GXLV.L.